Menu

Recent Interviews

Matthew Salthouse, CEO, Kainantu Resources

Matthew Salthouse
CEO | Kainantu Resources
3 Phillip Street #19-01 Royal Group Building, 048693 Singapore (SGP)

info@krl.com.sg

+65 6920 2020

Interview Kainantu Resources: "We hold the key to growth in the Asia-Pacific region".


Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

info@troilusgold.com

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".


John Jeffrey, CEO, Saturn Oil + Gas Inc.

John Jeffrey
CEO | Saturn Oil + Gas Inc.
Suite 1000 - 207 9 Ave SW, T2P 1K3 Calgary (CAN)

info@saturnoil.com

+1-587-392-7900

Saturn Oil + Gas CEO John Jeffrey: "Acquisition has increased production by 2,000%"


16. January 2020 | 11:53 CET

Aurora Cannabis, Canopy Growth, EXMceuticals - Profits with turnaround

  • Cannabis
Photo credits: pixabay.com

2019 was not a good year for investors in the cannabis sector with a long-term approach. After a never-ending rally in the years before, the party was over. However, the price capers can also be an opportunity to enter companies that are now one experience richer than they were a year ago in a champagne mood.

time to read: 1 minutes by Mario Hose
ISIN: CA30207T1049 , CA05156X1087 , CA1380351009


 

Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author


Share price recovery has begun

The shares of Aurora Cannabis changed hands in March 2019 in the peak at 13.67 CAD - the year before the historic high was even 16.24 CAD. What then followed was a flawless trend towards CAD 0.00, which ended last week at a low of CAD 1.96.

On yesterday's trading day, the share was traded at the closing price of 2.68 CAD. A return of over 36% within one week would have been theoretically possible. The market value of Aurora Cannabis is currently CAD 2.93 billion.

Clearly caught up from the low

With yesterday's closing price of 32.46 CAD and a current market value of 11.31 billion CAD, Canopy Growth is one of the top companies in the cannabis industry. In 2018 the shares changed hands at a peak of 76.68 CAD and last year the peak was 70.99 CAD.

The rapid price losses in phases ended in November at 18.23 CAD. Since then the share price has regained ground and hypothetically a performance of over 78% would have been possible from the low until yesterday.

Starting point for turnaround

For a long time, the stock of the newcomer EXMceuticals was excluded from the price capers of the well-known names. Although the share price was volatile, it nevertheless moved sideways between 0.87 CAD and 1.72 CAD. But in November 2019 the share price dropped further and was traded at CAD 0.45 at the beginning of 2020.

It now looks like it has bottomed out and could become the starting point for a turnaround. At yesterday's closing price of CAD 0.50, the company has a market value of CAD 18.28 million. The company yesterday announced further details of its development, it is continuing to make progress operationally.


Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

04. March 2021 | 09:16 CET | by Stefan Feulner

NanoRepro, EXMceuticals, Deutsche Telekom - The profiteers of the new world!

  • Cannabis

The world has changed since last year. The goal is to fight and contain the virus, which has destroyed our everyday life. In addition to the vaccine manufacturers such as BioNTech, AstraZeneca or Moderna, there are more and more new winners emerging from nowhere to become new stock market stars. Currently, the dominant topic, apart from the vaccination programs that are still hardly taking place in Germany, is the "national testing strategy." At the very least, this should enable a more regular and open life. Be there!

Read

07. December 2020 | 10:01 CET | by André Will-Laudien

EXMceuticals, Aurora, Xphyto Therapeutics - Cannabis 2.0 and Psilocybin!

  • Cannabis

The North American Cannabis Index has brought itself back to life in October! The index lost 80% since the beginning of 2019, but it's going up again with the survivors of the industry. Overall, the capitalization of the sector has decreased by 85%, with the election of Joe Biden, the second buying wave of purchases is underway. If hemp production was the initial focus, it is now the applications, the achieved market access and new active ingredient combinations. In the slipstream of the therapeutic plant customer, another topic came to the fore that has caused investors' hearts to stutter in recent weeks: the psychedelic drugs in the form of psilocybin. Psilocybin has been used as an entheogen and hallucinogenic drug since prehistoric times. Now the medical applications are being investigated. The trend is already running at full speed, the Canadian brokerage house Canaccord estimates the market volume of all indications that are suitable for treatment with active psychedelic ingredients to be USD 100 billion.

Read

15. July 2020 | 12:23 CET | by Mario Hose

BioNTech, EXMceuticals, XPhyto - Covid-19 and legalizations offer potential

  • Cannabis

In recent months, the society around the globe has been going through a process of change of deceleration and standstill. Priorities have been redefined and implemented at record speeds in many places. Covid-19 serves as a catalyst for change for many people. The reasons can be different. The development of corona vaccines and antibody tests will make a lot of money in the future and the legalization of cannabis in the USA on a federal level has the potential to create a renaissance.

Read